Farxiga (Dapagliflozin) Manufacturing, Supply Chain & Shortage History

Dapagliflozin, sold under the brand name Farxiga (and as Forxiga outside the United States), is an SGLT2 inhibitor taken as a once-daily oral tablet. It is distinct from GLP-1 receptor agonists such as semaglutide or tirzepatide, which are injectable peptides with a different manufacturing process and a different shortage history. This page focuses on manufacturing and supply questions specifically for Farxiga, not on dosing or individualized treatment decisions, which should come from a prescriber.

The direct answer

Dapagliflozin has not had a prolonged FDA-listed national shortage the way some injectable diabetes and weight-management drugs have. This is plausibly connected to the fact that it is an oral small molecule rather than a biologic, since chemical synthesis of small molecules generally scales across manufacturing sites more readily than cell-culture-based biologic production or injectable device fill-finish. Occasional, localized pharmacy stock-outs are still possible and have been reported anecdotally following the drug's heart failure and chronic kidney disease approvals, but these are distribution-level issues rather than evidence of a national supply failure. Readers should confirm current shortage status directly on the FDA Drug Shortage Database, since this status can change.

How dapagliflozin is manufactured

Dapagliflozin is produced through multi-step organic chemical synthesis rather than through a biologic process involving living cells. SGLT2 inhibitors as a drug class are built around a carbon-glycosidic (C-glucoside) bond that links a sugar-like moiety to the drug's core structure, a design feature widely described in the SGLT2 inhibitor pharmacology literature as conferring resistance to gut enzyme breakdown. The exact commercial synthetic route AstraZeneca currently uses is proprietary, and any specific published synthesis papers should be checked against the primary chemistry literature before being cited as the current manufacturing process, since process chemistry is often revised for yield and purity after initial publication.

Finished tablets are immediate-release and film-coated, available in 5 mg and 10 mg strengths, and are stable at room temperature according to the FDA-approved prescribing information, which removes the cold-chain requirement that complicates supply chains for injectable biologics.

AstraZeneca is headquartered in the United Kingdom and operates manufacturing capacity across multiple countries as part of its global pharmaceutical production network, per the company's own public sustainability and manufacturing disclosures (AstraZeneca sustainability reporting). Specific facility locations, capital investment figures, and safety-stock targets are not independently verified in this draft and should not be treated as confirmed figures until checked against AstraZeneca's current annual report or regulatory filings.

Regulatory approval timeline

The FDA approved dapagliflozin in January 2014 for glycemic control in adults with type 2 diabetes. The label was later expanded to include heart failure and chronic kidney disease indications, based on large cardiovascular and renal outcome trials (commonly referred to in the literature as DAPA-HF, DAPA-CKD, DELIVER, and DECLARE-TIMI 58). The direction of these trial results (reduced risk of the composite endpoints studied) is well established in cardiology and nephrology practice, but exact hazard ratios, confidence intervals, and enrollment numbers should be verified against the original New England Journal of Medicine publications rather than taken from secondary summaries, including this one. Current indication wording and dosing are set by the FDA-approved label, which should be checked directly for the most current wording.

Guideline bodies including the American Diabetes Association and cardiology/nephrology societies now treat SGLT2 inhibitors as a preferred or first-line option for appropriate patients with type 2 diabetes, heart failure, or chronic kidney disease. Exact guideline wording changes over time and should be checked against the current version of the relevant guideline rather than assumed static.

Each additional indication expanded the eligible patient population, which is the underlying reason manufacturing demand for Farxiga grew substantially after 2020. That is a reasonable inference from the sequence of approvals, not a documented internal AstraZeneca planning record.

Supply chain structure: what is plausible reasoning versus confirmed fact

AstraZeneca's general manufacturing model for oral small-molecule drugs typically separates active pharmaceutical ingredient (API) synthesis from tablet formation, coating, and packaging, with API synthesis usually concentrated at fewer qualified sites than finished-dose packaging. If that general pharmaceutical-manufacturing pattern holds for Farxiga, the API stage would be the more likely bottleneck point in any future disruption, since finished-dose packaging can more easily be shifted between contracted sites. This is a plausible structural inference based on how small-molecule drug manufacturing is generally organized, not a confirmed description of AstraZeneca's specific Farxiga facilities, which are not publicly detailed at the level needed to state this as fact.

FDA shortage-listing history

As of this article's last review date, dapagliflozin was not listed as an active shortage on the FDA Drug Shortage Database (FDA Drug Shortage Database). This contrasts with the extended shortage listings that affected some GLP-1 receptor agonists in recent years. Readers evaluating current availability should check the FDA database directly, since shortage status is time-sensitive and can change without notice.

Reports of localized pharmacy-level stock-outs following the 2020 and 2021 indication expansions circulated in trade and patient-facing sources, but a formal national FDA shortage notification for dapagliflozin is not documented in the sources available for this review. Any specific claim about the duration or scale of past localized shortages should be treated as unverified until confirmed against pharmacy trade press or FDA correspondence from that period.

How dapagliflozin works

Dapagliflozin inhibits the SGLT2 transporter in the kidney's proximal tubule, which under normal conditions reabsorbs most filtered glucose back into the bloodstream. Blocking this transporter causes glucose to be excreted in the urine, lowering blood glucose independent of insulin secretion or insulin sensitivity. This glycosuric effect also produces a mild osmotic diuresis, which is thought to contribute to the drug's cardiovascular and renal benefits observed in outcome trials, separate from its glucose-lowering effect. The proposed renal-protective mechanism involves changes in intraglomerular pressure through tubuloglomerular feedback, a mechanism distinct from and additive to renin-angiotensin-aldosterone system blockade. This is established pharmacology for the SGLT2 inhibitor class; individual patient response and dosing should be determined by a prescriber, not inferred from this general description.

Generic competition and what would actually change the supply picture

AstraZeneca holds patents on dapagliflozin that are expected to expire in the mid-to-late 2020s, though the exact expiration dates depend on patent term extensions and any pediatric exclusivity, and should be verified against current patent listings rather than assumed. Generic manufacturers can file an Abbreviated New Drug Application (ANDA) with the FDA to seek approval for a generic version once patent and exclusivity barriers clear. Once multiple generic manufacturers are producing dapagliflozin, total U.S. manufacturing capacity would be expected to increase and single-source disruption risk would be expected to decrease, following the general pattern seen with other small-molecule drugs after patent expiry. Whether specific generic manufacturers have already filed ANDAs for dapagliflozin, and the current status of those filings, is not confirmed in this draft and should be checked against the FDA's current ANDA and Orange Book listings before publication.

Decision framework: what to do if a pharmacy says Farxiga is unavailable

This framework is for the situation, not a substitute for medical advice, and it does not replace instructions from a prescriber.

Step 1: Confirm it is a local issue, not a national one. Check the FDA Drug Shortage Database directly for dapagliflozin's current listing status. If it is not listed, the problem is very likely local distribution, not a manufacturing failure.

Step 2: Ask the pharmacy to check alternate wholesalers or nearby locations. Most pharmacy stock-outs for a non-shortage-listed oral tablet resolve within days once a pharmacist checks a secondary distributor or a sister location.

Step 3: Decide whether the gap is short (days) or open-ended.

• If the pharmacy expects resupply within a few days and the patient has enough tablets to bridge the gap, waiting is often reasonable; confirm with the prescriber if there is any uncertainty.
• If the gap is open-ended or the patient has no remaining tablets, contact the prescriber before the next scheduled dose is missed by more than a day or two, since abrupt discontinuation removes the ongoing cardiac and renal protection associated with continued therapy in patients taking dapagliflozin for heart failure or CKD.

Step 4: Consider whether within-class substitution is reasonable, and let the prescriber decide. Other SGLT2 inhibitors, such as empagliflozin, are a different molecule with their own FDA label and their own outcome trial evidence base. Cardiovascular and renal outcome benefits are broadly treated as a class effect by diabetes and cardiology guideline bodies for SGLT2 inhibitors that have their own outcome trial data, but this is a prescriber decision that also depends on insurance formulary coverage, kidney function, and the specific indication being treated. Do not substitute without checking with the prescriber or pharmacist first.

Step 5: Know when a supply gap becomes an urgent problem. Stopping an SGLT2 inhibitor abruptly is not typically associated with a withdrawal syndrome, but patients with type 2 diabetes on multiple glucose-lowering agents, or patients with heart failure or advanced CKD, should not treat a several-day-or-longer interruption as inconsequential. Contact the prescribing clinician, and seek urgent care for symptoms such as unusual shortness of breath, rapid weight gain, significant swelling, or signs of very high blood glucose (excessive thirst, confusion, rapid breathing), since these can reflect underlying disease progression independent of the medication gap and warrant evaluation regardless of the cause.

What is established, what is plausible, and what is not established

Established: Dapagliflozin is an FDA-approved oral SGLT2 inhibitor manufactured by AstraZeneca, approved first for type 2 diabetes and later expanded to heart failure and chronic kidney disease indications. It works by blocking renal glucose reabsorption. It is a small molecule, not a biologic. It was not listed on the FDA Drug Shortage Database at last review.

Plausible but not independently confirmed here: The specific structure of AstraZeneca's manufacturing network, exact safety-stock policies, exact annual revenue figures, and the precise scale or duration of any past localized pharmacy stock-outs. These claims are reasonable extrapolations from how pharmaceutical supply chains generally work, but they are not confirmed against primary AstraZeneca filings or FDA correspondence in this review.

Not established: That dapagliflozin's supply is permanently immune to shortage risk. Small-molecule oral drugs are more resilient to certain supply disruptions than injectable biologics, but raw-material shortages, single-site API disruptions, or regulatory holds can still affect any manufacturer, and this article is not a guarantee of future availability.